
The BioCentury Show
BioCenturyAudio
- Format:
- Podcast
- New episodes:
- Every two weeks
- Typical length:
- about 35 minutes
- Latest episode:
About this show
Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine.
Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues.
The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine.
Don't miss this event, every two weeks, now available as a video webcast or audio podcast (https://www.biocentury.com/the-biocentury-show/watch-or-listen).
Covers: biopharma, biotech investment, clinical trials, drug development, genetic medicines, rare disease, china biotech, venture capital, pharmaceutical dealmaking, regulatory policy
Show details and episodes come from the publisher's public feed at rss.buzzsprout.com. Last updated . Names, artwork and text belong to their publishers.
Recently on this show
Summary of recent episodes, drawn from the publisher's feed.
The BioCentury Show is a podcast and video series where senior editors talk with scientists, executives, investors and policymakers about turning research into medicine. Recent episodes cover faster clinical trials in Texas, patient input in biotech investing, RNAi drug delivery, and genetic medicines for rare diseases.
Cosmos
Similar in subject
- BioCentury This Week
Both cover: biotech investment, china biotech, pharmaceutical dealmaking - The Biotech Startups Podcast
Both cover: drug development, clinical trials, venture capital - Business Of Biotech
Both cover: drug development, clinical trials, venture capital
Similar shows
Explore more
Episodes
Ep. 86 – Macrophages, ASCO & Clever-1: Faron CEO Juho Jalkanen on Bexmarilimab’s Promise
· 10 min
The macrophage field has seen its share of setbacks, but Faron believes bexmarilimab, its humanized mAb that binds to immune checkpoint target Clever-1, has what it takes to get across the goal line at FDA. On a special sponsored edition of The BioCentury Show, Juho Jalkanen, founder and CEO of Faron Pharmaceuticals, explains how the Finnish biotech landed on Clever-1, and why the target might more effectively repolarize macrophages than therapies against other macrophage checkpoints. Jalkanen also discusses the Phase I/II data Faron presented for bexmarilimab in myelodysplastic syndrome at the American Society of Clinical Oncology (ASCO) in Chicago, and what’s next for the immunotherapy. This episode of The BioCentury Show was sponsored by Faron (https://faron.com/). View full story: https://www.biocentury.com/article/656099 #biotech #biopharma #pharma #lifescience #ASCO #RandD #DrugDevelopment
Not rated yetEp. 85 - Stifel’s Opler on Trump 2.0's FDA & the Capital Markets
· 32 min
Notwithstanding the bad start that the Trump administration got off to on FDA, Tim Opler is optimistic that the agency will serve drug developers well, and sees enough good signals that the direction the agency is headed will not bring the difficult regulatory era that many in the industry feared. Opler, a managing director at Stifel, spoke to Editor in Chief Simone Fishburn on The BioCentury Show about why he’s optimistic about FDA, what he sees ahead for capital markets, competition in China, and three areas of innovation he’s focused on -- aging, women's health and the brain. View full story: https://www.biocentury.com/article/656040 #biotech #biopharma #pharma #lifescience #RandD #DrugDevelopment #FDA 00:00 - Introduction 01:30 FDA under Trump 2.0 08:07 State of Capital Markets 13:13 China Competition 17:09 Innovation: Aging, Women’s Health & the Brain
Not rated yetEp. 84 – Leadership Amid Turmoil: Moonlake CEO Jorge Santos Da Silva
· 29 min
As CEO of a vintage 2021 biotech, Jorge Santos Da Silva has had his leadership mettle tested by a pandemic, rising interest rates, a bear market, and a tumultuous U.S. policy environment — all while building the case for Moonlake’s lead program to become a top therapy for hidradenitis suppurativa and, eventually, a “pipeline-in-a-product.” The key for Santos Da Silva as founder and CEO of Moonlake Immunotherapeutics is to dial down the noise and focus on the key choices in front of you. “Moonlake has always existed in times of turmoil,” Santos Da Silva told Executive Editor Jeff Cranmer on The BioCentury Show, citing the recent M&A drought, high interest rates and political turmoil. “Understanding the situation from a cool perspective, being able to explain that to your people first, and then try to explain that to the Street and place the company in the right moment so that you have all the game in front of you" is his recipe for success as a CEO in biotech. Moonlake’s sonelokimab is expected to enter Phase III testing this year for HS; it's one of the most advanced multispecifics in the clinic for inflammation and immunology diseases. View full story: https://www.biocentury.com/article/655903 #biotech #biopharma #pharma #lifescience #RandD #DrugDevelopment 00:00 - Introduction 01:48 - Landscape for HS Therapies 09:03 - Market Opportunity 19:40 - Next Steps for Moonlake
Not rated yetEp. 83 – Europe’s Biotech Moment: Jérôme van Biervliet on Turning Uncertainty into Opportunity
· 31 min
Europe did not ask for this opportunity, says VIB’s Jérôme van Biervliet, but with FDA and the U.S. research funding situation headed into uncertain territory, it needs to use this moment to capitalize on its strengths in research, and address the shortcomings of its business and regulatory systems that have made it hard for biotech to fulfill its potential there. Van Biervliet is managing director of Flanders Institute for Biotechnology (VIB), a key player in the Belgian biotech landscape that has both a research arm and an investment unit. Ahead of BioCentury’s Bio€quity Europe conference in Bruges (https://bioequityeurope.com/), which will discuss how Europe can meet the complexity of this moment, he talked to BioCentury Editor in Chief Simone Fishburn on The BioCentury Show about the landscape unfolding in Europe, as well as where he sees innovation headed. View full story: https://www.biocentury.com/article/655818 #biotech #biopharma #pharma #LifeScience #ResearchFunding #EuropeanInnovation 00:00 - Introduction 02:03 - VIB’s Mission 07:52 - Europe’s Funding Opportunity 17:37 - Belgium’s Biotech Ecosystem 25:27 - Nanobodies’ Potential
Not rated yetEp. 82 – Act Now or Fall Behind: Michelle Rozo on Biotech’s National Security Stakes
· 31 min
The U.S. will cede its preeminence in biotechnology to China within three years unless the government acts urgently, an independent commission chartered by Congress warns. “Our window to act is closing,” the National Security Commission on Emerging Biotechnology said in a newly released report (https://www.biotech.senate.gov/final-report/chapters/). “We need a two-track strategy: make America innovate faster, and slow China down.” BioCentury Washington Editor Steve Usdin discusses the report's recommendations and warnings with the commission’s vice chair, Michelle Rozo, on The BioCentury Show. View full story: https://www.biocentury.com/article/655654 #biotech #biopharma #pharma #lifescience #politics #policy #law 00:00 - Introduction 03:56 - China Closing the Innovation Gap 09:20 - Slowing China Down 17:20 - Bolstering U.S. Biotech
Not rated yetEp. 81 - Data-Driven Growth: Immunocore CEO Bahija Jallal on Expanding TCR Therapies
· 30 min
On the latest episode of The BioCentury Show, Editor in Chief Simone Fishburn speaks with Bahija Jallal, CEO of Immunocore and the former president of Medimmune. While some biotechs are circumspect about gathering data during clinical trials that might not support the product in question, Jallal sees it as part of the obligation to patients and the field to learn as much as possible, as efficiently as possible. And that strategy has informed how the company will take its TCR technology into earlier lines of treatment and new indications. View full story:https://www.biocentury.com/article/655504 #biopharma #pharma #biotech #lifescience #RandD #DrugDevelopment #CEO 00:00 - Introduction 04:18 - Getting a New Modality to Market 17:15 - Infectious Pipeline 22:04 - Autoimmune Pipeline 27:24 - Leading in Challenging Times
Not rated yetEp. 80 - Vertex’s Winning Formula: Altshuler on Choosing the Next Breakthroughs
· 32 min
Vertex’s approach to research, defined over a decade ago to beat the dismal odds of success in biotech, remains core to its strategy, even as the industry evolves and technologies expand. While that strategy, which EVP and CSO David Altshuler calls “serial innovation,” has seen the company launch eight drugs since 2011 and jump market cap tiers (https://www.biocentury.com/article/648865)on the success of its cystic fibrosis portfolio, it’s now being tested in other areas as Vertex expands to pain, renal disease, Type I diabetes, and more. In conversation with Editor in Chief Simone Fishburn on The BioCentury Show, Altshuler discussed the rising interest in causal biology and the role of AI, noting that the fundamentals of picking targets and programs have not changed. View full story: https://www.biocentury.com/article/655408 #biotech #biopharma #pharma #lifescience #RandD #DrugDevelopment #AI 00:00 - Introduction 02:12 - Causal Biology 08:48 - AI in R&D, at Vertex 16:35 - Academia-Industry Interface 22:00 - Cell Therapy for Diabetes 25:35 - Gene Therapy for DMD
Not rated yetEp. 79 - BNP Paribas’ Moneer on Biotech’s Bull Case: M&A, PE, and Market Recovery
· 29 min
Since the annual J.P. Morgan Healthcare Conference in San Francisco in early January, biotech has seen a notable surge in enthusiasm, Zahid Moneer, senior managing director of investment banking at BNP Paribas, told The BioCentury Show. Moneer, who is more upbeat than many in today’s biopharma sector, sees capital raises from million-dollar seed rounds to nine-digit series A, B, and C rounds driving significant growth alongside M&A activity. In the interview, he also also highlights the growing role of private equity firms in biopharma and the trend of pharmas engaging earlier with biotechs and investors looking to deploy capital into those companies View full story: https://www.biocentury.com/article/655216 #biotech #biopharma #pharma #lifescience #financing #privateequity #IPO 00:00 - Introduction 00:37 - Investment Climate 05:06 - Pharma M&A Activity 15:25 - Private Equity's Role 21:44 - Biotech Financing
Not rated yetEp. 78 - Biotech’s New Normal: SR One’s Simeon George on Adapting to Market Constraints
· 31 min
Biotechs need to get used to the new normal, says SR One CEO and Managing Partner Simeon George, and that will require significant adjustments to the business model. This new normal comes from an extended tough capital environment against a backdrop of political uncertainty, but while biotechs face a different set of factors than they have in the past, there are still first principles of value creation that should guide them. George, who co-founded SR One management in 2020 following its spinout from GSK, spoke on The BioCentury Show with Editor in Chief Simone Fishburn about the challenges facing biotechs and how VCs are navigating through the complexity of the moment. He also discussed SR One’s strategy and philosophy of investing. View full story: https://www.biocentury.com/article/655142 00:00 - Introduction 01:31 - Meeting the Moment 04:45 - Company Valuations 13:54 - China Strategy, NewCos 22:08 - Building Successful Biotechs #biotech #biopharma #pharma #lifescience #CEO #financing #newco
Not rated yetEp. 77 - AI’s Next Leap: Foresite Labs’ Vik Bajaj on Predictive Biology
· 35 min
Clinical trials will be launched in the next year or two to test predictions about causal biology made by artificial intelligence models, Vik Bajaj, co-founder and CEO of Foresite Labs and managing director of Foresite Capital Management, believes. Foresite teamed up with Arch Venture Partners last year on a $1 billion venture round to fund Xaira Therapeutics, which aims to reinvent the R&D process via AI-driven protein design and biological discovery technologies (https://www.biocentury.com/article/652304). Bajaj, who serves as interim president of Xaira, discussed the potential for artificial intelligence to accelerate biomedical progress in an interview with Washington Editor Steve Usdin on The BioCentury Show. View full story: https://www.biocentury.com/article/654977 #biotech #biopharma #pharma #lifescience #AI #RandD #drugdiscovery 00:00 - Introduction 01:18 - AI & Biotech 12:19 - Getting the Data Right 19:06 - Healthcare Delivery 30:47 - Making It Real
Not rated yet